Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia

Jeffrey R Bishop; Del D Miller; Vicki L Ellingrod; Timothy Holman

doi:10.1002/hup.1163

$Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia$

Journal article

Open access

Peer reviewed

Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia

Jeffrey R Bishop, Del D Miller, Vicki L Ellingrod and Timothy Holman

Human psychopharmacology, Vol.26(1), pp.28-34

01/2011

DOI: 10.1002/hup.1163

PMCID: PMC3199025

PMID: 21344500

Files and links (1)

url

https://doi.org/10.1002/hup.1163View

Published (Version of record) Open Access

Abstract

Positive associations between polymorphisms in the type-three metabotropic glutamate receptor gene (GRM3) and the pathogenesis of schizophrenia as well as response to antipsychotic treatment have been reported. The objective of this study was to determine whether refractory psychiatric symptoms in antipsychotic non-responders are related to polymorphisms in GRM3. Ninety-five treatment refractory schizophrenia participants were enrolled. Prior to a medication switch, global psychopathology and negative symptoms were rated. These participants were genotyped for seven markers in GRM3. Genotype associations with symptoms were assessed. Two markers in GRM3 (rs1989796 and rs1476455), were associated with the presence of refractory global symptoms as measured by the Brief Psychiatric Rating Scale (BPRS) Total scores. Participants with an rs1476455_CC genotype had significantly higher BPRS scores than A-carriers (55.1±10.4 vs. 48.3±9.2; F=7.6, p=0.0071). Additionally, participants with the rs1989796_CC genotype had significantly higher BPRS scores than T-carriers (50.1±5.7 vs. 55.8±10.5, F=7.1, p=0.0091). No evidence for significant associations with negative symptoms was observed. Polymorphisms in the GRM3 gene may be associated with refractory global psychosis symptoms but not negative symptoms in persons with schizophrenia.

Humans

Middle Aged

Genotype

Male

Schizophrenic Psychology

Psychiatric Status Rating Scales

Schizophrenia - genetics

Receptors, Metabotropic Glutamate - genetics

Schizophrenia - physiopathology

Adult

Female

Polymorphism, Single Nucleotide

Antipsychotic Agents - pharmacology

Schizophrenia - drug therapy

Details

Title: Subtitle: Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia
Creators: Jeffrey R Bishop - Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, Illinois 60612, USA. jbishop@uic.edu
Del D Miller
Vicki L Ellingrod
Timothy Holman
Resource Type: Journal article
Publication Details: Human psychopharmacology, Vol.26(1), pp.28-34
Publisher: England
DOI: 10.1002/hup.1163
PMID: 21344500
PMCID: PMC3199025
ISSN: 0885-6222
eISSN: 1099-1077
Grant note: K23 MH001758-05 / NIMH NIH HHS K08MH083888 / NIMH NIH HHS R01 MH082784 / NIMH NIH HHS K23 MH001758 / NIMH NIH HHS K08 MH083888 / NIMH NIH HHS K08 MH064158 / NIMH NIH HHS K08MH64158 / NIMH NIH HHS K23MH01758 / NIMH NIH HHS M01-RR-59 / NCRR NIH HHS K08 MH064158-05 / NIMH NIH HHS K08 MH083888-01A1 / NIMH NIH HHS
Language: English
Date published: 01/2011
Academic Unit: Psychiatry
Record Identifier: 9984003458102771

Metrics

27 Record Views

18 Times Cited - Web of Science

See more details